Irish biopharmaceutical firm Horizon Pharma has completed the acquisition of US-based Hyperion Therapeutics for around $1.1bn.

The deal was first announced at the end of March.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Horizon noted that acquisition of Hyperion has been completed following successful tender for 86% of its outstanding shares.

"This is a transformational transaction for Horizon Pharma and adds two important medicines, Ravicti and Buphenyl, which will help strengthen our orphan business and set the foundation for continued growth."

Under the deal, Horizon purchased all the issued and outstanding shares of Hyperion’s common stock for $46.00 per share in cash.

Horizon Pharma president and CEO Timothy Walbert said: "This is a transformational transaction for Horizon Pharma and adds two important medicines, Ravicti and Buphenyl, which will help strengthen our orphan business and set the foundation for continued growth.

See Also:

"Above all else, Horizon Pharma is a ‘patients first’ company, so our goal through the integration of these medicines into our portfolio is to ensure continued access for the patients receiving treatment and the physicians who treat them."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Ravicti and Buphenyl medicines have been developed to treat people with urea cycle disorders (UCDs), a combination of inherited metabolic problems.

Horizon noted that marketing authorisation application was filed for European marketing of Ravicti. Being marketed in the US, Ravicti (glycerol phenylbutyrate) oral liquid received approval in the US in February 2013.

Horizon produces products for arthritis, inflammation and orphan diseases, including Actimmune (interferon gamma-1b), Duexis (ibuprofen/famotidine), Pennsiad (diclofenac sodium topical solution) 2% w/w, Rayos (prednisone) delayed-release tablets and Vimovo (naproxen/esomeprazole magnesium).